{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalGuideline"
  ],
  "@id": "health-sciences:medicine:neurology:neuro-005",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:54:58.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "neurology-knowledge-base"
    ],
    "confidence": 0.96,
    "status": "validated",
    "modified": "2026-01-11T14:58:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/neurology",
    "type": "management",
    "difficulty": "intermediate",
    "importance": "critical",
    "aku_id": "005",
    "keywords": [
      "stroke prevention",
      "secondary prevention",
      "antiplatelet",
      "anticoagulation",
      "carotid endarterectomy",
      "risk factors"
    ],
    "medical_specialty": "neurology",
    "clinical_context": "cerebrovascular_disease"
  },
  "content": {
    "title": "Stroke Prevention (Secondary Prevention)",
    "summary": "Evidence-based strategies to prevent recurrent stroke after ischemic stroke or TIA",
    "key_points": [
      "Antiplatelets for non-cardioembolic stroke; anticoagulation for cardioembolic (AF)",
      "High-intensity statin for all atherosclerotic strokes",
      "BP target <130/80 after acute phase",
      "Carotid intervention for symptomatic stenosis \u226550%",
      "DAPT for 21-90 days after high-risk TIA/minor stroke",
      "Address modifiable risk factors: smoking, diabetes, obesity"
    ],
    "statement": {
      "text": "Secondary stroke prevention is tailored to stroke mechanism: antiplatelets for non-cardioembolic, anticoagulation for AF, high-intensity statins for atherosclerotic disease, blood pressure control, carotid intervention for significant symptomatic stenosis, and aggressive risk factor modification.",
      "formal": "Stroke Prevention = Mechanism-specific treatment (antiplatelet vs anticoagulation) + Statin + BP control + Carotid intervention if indicated + Lifestyle modification"
    },
    "explanation": {
      "intuition": "Preventing a second stroke is about understanding why the first one happened and blocking that pathway. If it was a clot from the heart (AF), blood thinners are key. If it was from a narrowed neck artery, fix the narrowing. If it was from small vessel disease, control blood pressure.",
      "key_insight": "The first 90 days after stroke/TIA carry the highest recurrence risk. This is when aggressive, mechanism-specific therapy has the greatest impact. Long-term, risk factor modification (especially BP and smoking) provides sustained benefit."
    },
    "definitions_glossary": {
      "secondary_prevention": "Preventing recurrent stroke after index event",
      "antiplatelet_therapy": "Aspirin, clopidogrel, or combination to prevent arterial thrombosis",
      "anticoagulation": "DOACs or warfarin for cardioembolic stroke prevention",
      "high_intensity_statin": "Atorvastatin 40-80mg or rosuvastatin 20-40mg; LDL target <70",
      "carotid_endarterectomy": "Surgical removal of atherosclerotic plaque from carotid artery",
      "carotid_artery_stenting": "Endovascular stent placement as alternative to CEA",
      "symptomatic_stenosis": "Carotid narrowing causing ipsilateral stroke/TIA",
      "cryptogenic_stroke": "Stroke without identified cause despite workup; consider PFO, occult AF",
      "modifiable_risk_factors": "HTN, DM, smoking, obesity, dyslipidemia, physical inactivity",
      "ESUS": "Embolic stroke of undetermined source - subset of cryptogenic",
      "patent_foramen_ovale": "PFO - atrial septal communication allowing paradoxical embolism",
      "paradoxical_embolism": "Venous thrombus crossing PFO to arterial circulation causing stroke"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "recurrence_risk": "Without treatment: 10-15% at 1 year; with optimal prevention: 3-5%",
      "mechanism_specific": {
        "atherosclerotic": "Plaque instability \u2192 antiplatelets, statins, BP control",
        "cardioembolic": "Stasis \u2192 anticoagulation (DOACs for AF)",
        "small_vessel": "Lipohyalinosis \u2192 BP control",
        "other": "Dissection, hypercoagulable, vasculitis \u2192 treat underlying cause"
      }
    },
    "treatment_options": {
      "antiplatelets": {
        "aspirin": "81-325mg daily; first-line for non-cardioembolic",
        "clopidogrel": "75mg daily; alternative to aspirin",
        "DAPT": "Aspirin + clopidogrel \u00d7 21-90 days for high-risk TIA/minor stroke (CHANCE, POINT)",
        "aspirin_dipyridamole": "Alternative; less commonly used"
      },
      "anticoagulation": {
        "indication": "Cardioembolic stroke (AF, mechanical valve, LV thrombus)",
        "DOACs": "Apixaban, rivaroxaban, dabigatran, edoxaban - preferred for AF",
        "warfarin": "Mechanical valve, severe mitral stenosis",
        "timing": "Start after imaging confirms no hemorrhagic transformation (typically 2-14 days based on infarct size)"
      },
      "statin_therapy": {
        "high_intensity": "Atorvastatin 40-80mg or rosuvastatin 20-40mg",
        "LDL_target": "<70 mg/dL for atherosclerotic stroke",
        "benefit": "Reduces recurrent stroke, MI, vascular death"
      },
      "blood_pressure": {
        "target": "<130/80 mmHg (after acute phase)",
        "agents": "Thiazide, ACEi, ARB, CCB; individualized",
        "benefit": "Each 10mmHg reduction \u2192 30% relative risk reduction"
      },
      "carotid_intervention": {
        "CEA_indication": "Symptomatic stenosis \u226550% (NASCET); \u226570% has greatest benefit",
        "timing": "Within 2 weeks of event for maximum benefit",
        "CAS": "Alternative for high surgical risk; similar outcomes for most"
      },
      "PFO_closure": {
        "indication": "Cryptogenic stroke age <60 with high-risk PFO features",
        "trials": "CLOSE, RESPECT, REDUCE showed benefit over medical therapy alone"
      },
      "lifestyle": [
        "Smoking cessation (50% risk reduction)",
        "Weight loss if obese",
        "Regular exercise",
        "Mediterranean diet",
        "Moderate alcohol"
      ]
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Stroke Prevention"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "Secondary Stroke Prevention"
      },
      {
        "@language": "en",
        "@value": "Stroke Risk Factor Management"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "Evidence-based strategies to prevent recurrent stroke after ischemic stroke or TIA, including mechanism-specific therapy and risk factor modification"
    },
    "notation": "neuro-005"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "230690007",
      "description": "Cerebrovascular disease (disorder)",
      "matchType": "broadMatch"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D002561",
      "uri": "http://id.nlm.nih.gov/mesh/D002561",
      "description": "Cerebrovascular Disorders",
      "matchType": "broadMatch"
    }
  ],
  "pedagogical": {
    "target_audience": [
      "internal_medicine_residents",
      "neurology_residents",
      "primary_care_physicians"
    ],
    "estimated_time": "35min",
    "difficulty_curve": 0.68,
    "learning_objectives": [
      "Select antiplatelet vs anticoagulation based on stroke mechanism",
      "Apply DAPT for high-risk TIA/minor stroke",
      "Know indications and timing for carotid intervention",
      "Target LDL <70 with high-intensity statin",
      "Identify modifiable risk factors"
    ],
    "clinical_pearls": [
      "DAPT \u00d7 21-90 days after high-risk TIA reduces recurrence by 25% (CHANCE, POINT)",
      "Don't delay carotid intervention - benefit greatest within 2 weeks",
      "BP control is most impactful long-term modifiable factor",
      "Smoking cessation reduces stroke risk by 50%",
      "Young cryptogenic stroke: consider PFO closure if high-risk features"
    ],
    "board_yield": {
      "usmle_step2": "Very High",
      "internal_medicine_boards": "Critical"
    }
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "health-sciences:medicine:neurology:neuro-001",
        "title": "Ischemic Stroke",
        "strength": 1.0
      },
      {
        "id": "health-sciences:medicine:neurology:neuro-004",
        "title": "TIA",
        "strength": 0.95
      }
    ],
    "skos:related": [
      {
        "@id": "health-sciences:medicine:cardiology:cardio-007",
        "@type": "skos:Concept",
        "skos:prefLabel": "Atrial Fibrillation"
      },
      {
        "@id": "health-sciences:medicine:cardiology:cardio-050",
        "@type": "skos:Concept",
        "skos:prefLabel": "Lipid Management"
      }
    ],
    "owl:sameAs": [
      "http://www.wikidata.org/entity/Q12202"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T14:58:00.000Z",
    "sources": [
      {
        "source": "Kleindorfer DO, et al. 2021 AHA/ASA Secondary Stroke Prevention Guideline. Stroke 2021",
        "type": "clinical_guideline",
        "year": 2021,
        "confidence": 1.0
      }
    ]
  },
  "quality_assessment": {
    "CQS": 0.94,
    "completeness": 0.95,
    "accuracy": 0.97,
    "clarity": 0.94,
    "pedagogical_quality": 0.93,
    "ontology_alignment": 0.95,
    "last_assessment": "2026-01-11T14:58:00.000Z",
    "assessor": "quality-enhancement-agent"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Stroke",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q12202"
}